- Home
- TLSI vs THRD Comparison
TLSI vs THRD Comparison
Compare TLSI & THRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- THRD
- Stock Information
- Founded
- TLSI 2010
- THRD 2019
- Country
- TLSI United States
- THRD United States
- Employees
- TLSI N/A
- THRD N/A
- Industry
- TLSI Medical Specialities
- THRD Biotechnology: Pharmaceutical Preparations
- Sector
- TLSI Health Care
- THRD Health Care
- Exchange
- TLSI Nasdaq
- THRD Nasdaq
- Market Cap
- TLSI 204.0M
- THRD 238.7M
- IPO Year
- TLSI N/A
- THRD 2022
- Fundamental
- Price
- TLSI $4.56
- THRD $5.41
- Analyst Decision
- TLSI Strong Buy
- THRD Hold
- Analyst Count
- TLSI 5
- THRD 3
- Target Price
- TLSI $10.90
- THRD $5.00
- AVG Volume (30 Days)
- TLSI 134.8K
- THRD 211.0K
- Earning Date
- TLSI 08-13-2025
- THRD 08-07-2025
- Dividend Yield
- TLSI N/A
- THRD N/A
- EPS Growth
- TLSI N/A
- THRD N/A
- EPS
- TLSI N/A
- THRD N/A
- Revenue
- TLSI $32,141,000.00
- THRD N/A
- Revenue This Year
- TLSI $55.39
- THRD N/A
- Revenue Next Year
- TLSI $54.89
- THRD N/A
- P/E Ratio
- TLSI N/A
- THRD N/A
- Revenue Growth
- TLSI 46.20
- THRD N/A
- 52 Week Low
- TLSI $3.50
- THRD $3.18
- 52 Week High
- TLSI $6.04
- THRD $16.02
- Technical
- Relative Strength Index (RSI)
- TLSI 39.21
- THRD 51.37
- Support Level
- TLSI $4.41
- THRD $5.40
- Resistance Level
- TLSI $4.73
- THRD $5.47
- Average True Range (ATR)
- TLSI 0.22
- THRD 0.05
- MACD
- TLSI -0.02
- THRD -0.01
- Stochastic Oscillator
- TLSI 18.99
- THRD 8.00
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About THRD Third Harmonic Bio Inc.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.